Allied Neurology & Interventional Pain Practice at NJAJ Meadowlands Seminar
The New Jersey Association for Justice NJAJ - Meadowlands Seminar took place Wednesday – Friday, December 8 – 10, 2021 in East Rutherford, New Jersey. This seminar was one of three annual meetings hosted by the New Jersey Association for Justice Educational Foundation, Inc. aimed at providing quality trial lawyer education. After two years, the seminar was finally able to b More»



HomeBlog › Mild COVID-19 Is Not Necessarily Benign

Mild COVID-19 Is Not Necessarily Benign


Eight months after contracting mild COVID-19, many healthcare workers reported persistent symptoms and functional impairment.

Substantial numbers of patients hospitalized with COVID-19 have lingering symptoms several months after discharge. What happens after mild disease? Researchers in Sweden invited healthcare professionals with mild COVID-19 (age range, 33–56; 85% women) to complete baseline questionnaires and have blood samples tested every 4 months for SARS-CoV-2 anti-spike IgG. At the 8-month follow up, 323 seropositive and 1072 seronegative participants reported on persistence, severity, and duration of 23 predefined symptoms. Underlying chronic conditions were reported by 23% of participants regardless of serostatus.

At least 1 moderate-to-severe symptom lasting ≥2 months was reported by 26% (seropositive) versus 9% (seronegative) participants; symptoms lasting ≥8 months were reported by 15% versus 3% of seropositive and seronegative participants, respectively. The most common symptoms reported by seropositive participants were anosmia, fatigue, ageusia, and dyspnea. Seropositive participants reported that persistent symptoms moderately to markedly disrupted their work life (8%), social life (15%), or home life (12%).


This study confirms that even mild COVID is not necessarily benign, as approximately one quarter of these low-risk individuals with mild COVID-19 reported persistent symptoms 2 months after illness that negatively affected daily lives. Understanding the pathogenesis of and potential therapeutic interventions for this condition, now known as post-acute COVID-19 syndrome, is urgently needed.

Carlos del Rio, MD, reviewing Havervall S et al. JAMA 2021 Apr 7